1 / 55

Rheumatoid Arthritis Systemic chronic inflammatory disease Mainly affects synovial joints

Rheumatoid Arthritis Systemic chronic inflammatory disease Mainly affects synovial joints Variable expression Prevalence about 3% Worldwide distribution Female:male ratio 3:1 Peak age of onset: 25-50 years. Rheumatoid Arthritis. Unknown etiology Genetics Environmental

lise
Télécharger la présentation

Rheumatoid Arthritis Systemic chronic inflammatory disease Mainly affects synovial joints

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rheumatoid Arthritis Systemic chronic inflammatory disease Mainly affects synovial joints Variable expression Prevalence about 3% Worldwide distribution Female:male ratio 3:1 Peak age of onset: 25-50 years

  2. Rheumatoid Arthritis • Unknown etiology • Genetics • Environmental • Possible infectious component • Autoimmune disorder

  3. THE PATHOLOGY OF RA • Serositis 1. Synovitis Joints Tendon sheaths Bursae • Nodules • Vasculitis

  4. RA Is Characterised by Synovitis and Joint Destruction NORMAL RA Inflamed synovial membrane Synovial membrane • Major cell types: • T lymphocytes • macrophages Pannus Cartilage • Minor cell types: • fibroblasts • plasma cells • endothelium • dendritic cells Synovial fluid • Major cell type: • neutrophils Capsule Cartilage thinning Adapted from Feldmann M, et al. Annu Rev Immunol. 1996;14:397-440.

  5. Numerous Cellular Interactions Drive the RA Process Immune complexes Bacterial products IL-1, TNF-, etc Rheumatoid factors B cell IL-1 Soluble factors and direct cell–cell contact T cell HLA -DR Antigen- presenting cells Macrophage B cell or macrophage IL-1 and TNF- Synoviocytes Chondrocytes Pannus Articular cartilage Production of collagenase and otherneutral proteases Arend W. Semin Arthritis Rheum. 2001;30(suppl 2):1-6.

  6. IL-1 and TNF- Have a Number of Overlapping Proinflammatory Effects Proinflammatory effects of IL-1 Proinflammatory effects of TNF- COX-2PGE2NOAdhesion moleculesChemokinesCollagenasesIL-6 TNF-Osteoclast activation Angiogenic factors IL-1 cell death COX-2 = cyclo-oxygenase type 2; PGE2 = prostaglandin-E2; NO = nitric oxide

  7. IL-1 Plays a Pivotal Role in the Inflammatory and Destructive Processes of RA IL-1 Activates monocytes/macrophages Induces fibroblast proliferation Activates chondrocytes Activates osteoclasts Inflammation Synovial pannus formation Cartilage breakdown Bone resorption

  8. Signs and Symptoms • Joint inflammation • Tender, warm swollen joints • Symmetrical pattern • Pain and stiffness • Symptoms in other parts of the body • Nodules • Anemia • Fatigue, occasional fever, malaise

  9. JOINT INVOLVEMENT ON PRESENTATION OF RA Polyarticular 75% Monoarticular 25% Small joints Knee 50% of hands and feet 60% Large joints 30% Shoulder } Wrist } Large and Hip } 50% Small joints 10% Ankle } Elbow }

  10. Articular features seen in the Rheumatoid Hand WRIST:PIPs: Synovitis Synovitis Prominent ulnar styloid Fixed flexion or extension Subluxation and collapse of deformities carpus (Swan neck or boutonniere Radial deviation deformity) MCPs: THUMBS: Synovitis Synovitis Ulnar deviation ‘Z’ deformity Subluxation

  11. Joint Destruction

  12. Extra-articular manifestations • General • fever, lymphadenopathy, weight loss, fatigue • Dermatologic • palmar erythema, nodules, vasculitis • Ocular • episcleritis/scleritis, scleromalacia perforans, choroid and retinal nodules

  13. Extra-articular manifestations • Cardiac • pericarditis, myocarditis, coronary vasculitis, nodules on valves • Neuromuscular • entrapment neuropathy, peripheral neuropathy, mononeuritis multiplex • Hematologic • Felty’s syndrome, large granular lymphocyte syndrome, lymphomas

  14. Extra-articular manifestations • Pulmonary • pleuritis, nodules, interstitial lung disease, bronchiolitis obliterans, arteritis, effusions • Others • Sjogren’s syndrome, amyloidosis

  15. Investigations: • Hematology : CBC , ESR • Biochemistry : LFT , Renal profile • Serology : RF , Anti-CCP • Radiography : Joints , Spines ,Chest

  16. Treatment Goals • Relieve pain • Reduce inflammation • Prevent/slow joint damage • Improve functioning and quality of life

  17. Treatment Approaches • Lifestyle modifications • Rest • Physical and occupational therapy • Medications • Surgery

  18. Rationale for the Early Treatment of R.A. • •Erosions develop early in the disease course • •Destruction is irreversible • •Disease activity is strongly associated with joint destruction later in the disease course • •Early treatment can slow down radiographic progress • •Disease activity must be suppressed maximally in its early stages to prevent destruction and preserve function

  19. Drug Treatments • Nonsteroidal anti-inflammatory drugs (NSAIDs) • Disease-modifying antirheumatic drugs (DMARDs) • Biologic response modifiers • Corticosteroids

  20. Traditional NSAIDs Aspirin Ibuprofen Ketoprofen Naproxen COX-2 Inhibitors Celecoxib Rofecoxib Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

  21. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) • To relieve pain and inflammation • Use in combination with a DMARD • Gastrointestinal side effects

  22. Hydroxychloroquine Sulfasalazine Methotrexate Leflunomide Gold Azathioprine Disease-Modifying Antirheumatic Drugs (DMARDs)

  23. Disease-Modifying Antirheumatic Drugs (DMARDs) • Control symptoms • No immediate analgesic effects • Can delay progression of the disease (prevent/slow joint and cartilage damage and destruction) • Effects generally not seen until a few weeks to months

  24. DMARDs • hydroxychloroquine • mild non-erosive disease • combinations • 200 mg bid • eye exams

  25. DMARDs • Sulfasalazine • 1 gm bid - tid • CBC, LFTs • onset 1 - 2 months • Methotrexate • most commonly used drug • fast acting (4-6 weeks) • po, SQ - weekly • CBC, LFTs

  26. DMARDs • IM Gold • slow onset (3-6 months) • weekly then monthly injections • CBC, UA before each injection • Oral Gold • less effective • slow acting (4-6 months) • daily • CBC, UA

  27. Biologic Response Modifiers • Etanercept • Infliximab • Anakinra

  28. Biologic Response Modifiers • Etanercept and infliximab target tumor necrosis factor alpha (TNF-) • Anakinra targets interleukin-1 receptor

  29. OSTEOARTHRITIS

  30. MULTIFACTORAL ETIOLOGY OF OA ● Joint instability ● Age ● Hormonal factors ● Trauma ● Altered biochemistry ● Inflammation ● Genetic predisposition ● ? Others

  31. SYMPTOMS AND SIGNS OF OA • Pain – worse on use of joint • Stiffness – mild after immobility • Loss of movement • Pain on movement/restricted range • Tenderness (articular or periarticular) • Bony swelling • Soft tissue swelling • Joint crepitus

  32. RADIOLOGICAL FEATURES OF OA • Narrowing of joint space • Osteophytosis • Altered bone contour • Bone sclerosis and cysts • Periarticular calcification • Soft-tissue swelling

More Related